KR101344055B1 - Composition for improving liver function containing fermented liquor of Codonopsis lanceolata extract as effective component - Google Patents
Composition for improving liver function containing fermented liquor of Codonopsis lanceolata extract as effective component Download PDFInfo
- Publication number
- KR101344055B1 KR101344055B1 KR1020120058460A KR20120058460A KR101344055B1 KR 101344055 B1 KR101344055 B1 KR 101344055B1 KR 1020120058460 A KR1020120058460 A KR 1020120058460A KR 20120058460 A KR20120058460 A KR 20120058460A KR 101344055 B1 KR101344055 B1 KR 101344055B1
- Authority
- KR
- South Korea
- Prior art keywords
- deodeok
- extract
- liver function
- lactic acid
- fermented
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 87
- 230000003908 liver function Effects 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 241000756943 Codonopsis Species 0.000 title description 3
- 235000013402 health food Nutrition 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 14
- 240000001929 Lactobacillus brevis Species 0.000 claims description 9
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 235000020183 skimmed milk Nutrition 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 82
- 239000004310 lactic acid Substances 0.000 description 41
- 235000014655 lactic acid Nutrition 0.000 description 41
- 241000894006 Bacteria Species 0.000 description 33
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 32
- 238000000855 fermentation Methods 0.000 description 32
- 230000004151 fermentation Effects 0.000 description 32
- 239000000047 product Substances 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 229960005489 paracetamol Drugs 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 210000003494 hepatocyte Anatomy 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 9
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 150000007524 organic acids Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 235000021067 refined food Nutrition 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000019784 crude fat Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002443 hepatoprotective effect Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000013324 preserved food Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ILLQPJDSZOHAOW-UHFFFAOYSA-N 1-methyl-3,4-dihydropyrido[3,4-b]indole-2-carbaldehyde Chemical compound C(=O)N1C(C)=C2N=C3C=CC=CC3=C2CC1 ILLQPJDSZOHAOW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000020992 canned meat Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- FOTDHUVOUZZTTB-UHFFFAOYSA-N cyclobuten-1-ol Chemical compound OC1=CCC1 FOTDHUVOUZZTTB-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000020536 functional hot beverage Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- -1 perlolyne Natural products 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/121—Brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
Abstract
본 발명은 더덕 추출물의 발효물을 유효성분으로 함유하는 간기능 개선용 조성물 및 간 기능 개선용 건강식품을 제공한다.The present invention provides a composition for improving liver function and a health food for improving liver function containing the fermented product of Deodeok extract.
Description
본 발명은 더덕 추출물의 발효물을 유효성분으로 함유하는 간기능 개선용 조성물에 관한 것으로서, 더욱 상세하게는 더덕 추출물의 발효물을 유효성분으로 함유하는 간기능 개선용 조성물 및 간 기능 개선용 건강식품에 관한 것이다. The present invention relates to a composition for improving liver function containing the fermented product of Deodeok extract as an active ingredient, and more particularly, a composition for improving liver function and a liver food improving composition containing the fermented product of Deodeok extract as an active ingredient. It is about.
최근 한국인의 건강수준에서 간암에 의한 사망률은 10만 명당 23.4명으로 세계 1위이고 만성 간질환의 경우도 28.8명으로 3번째로 조사되었다. 또한 최근 통계청에서 우리나라 40대의 경우 인구 10만 명당 56.1명이 간질환으로 가장 높은 사망원인으로 발표하였다. 과음으로 인한 알코올성 간질환은 지방간, 알코올성 간염, 알코올성간경변증 등이 있으며, 정신적 스트레스와 흡연으로 간 손상을 가중시켜 인체가 방어 해독 작용을 하지 못해 면역 체계에 이상을 가져와 다른 질병의 원인이 되기도 한다. 이러한 간 관련 질병에 의한 폐해가 커짐에 따라서 간 관련 치료제 시장뿐만 아니라 건강기능성 식품시장에도 간 기능성 개선 제품에 대한 관심과 소비자의 요구도가 높아지고 있는 실정이다. In Korea, the mortality rate of liver cancer was 23.4 per 100,000 people in the world, the first in the world, and the chronic liver disease was the third in 28.8 cases. In recent years, the National Statistical Office (NSO) has reported that 56 deaths per 100,000 population in Korea are among the highest causes of liver disease. Alcoholic liver disease caused by excessive drinking, such as fatty liver, alcoholic hepatitis, alcoholic cirrhosis, etc., aggravate the liver damage due to mental stress and smoking, the body's defense and detoxification effect can cause the immune system and cause other diseases. As the damage caused by the liver-related diseases increases, the interest and demand of consumers for the liver functional improvement products are increasing not only in the liver-related therapeutic market but also in the health functional food market.
더덕(Codonopsis lanceolata)은 도라지과(Campanulaceae)에 속하는 다년생 초본으로, 예로부터 뿌리를 양유(Radix Codonopsis lanceolata)라 하여 인삼대용으로 사용해 왔다. 한방에선 진해, 거담, 해독, 천식 등에 사용하였고 특유의 풍미와 탄수화물, 단백질 외에도 칼슘, 인, 철분 등 무기질과 비타민이 풍부하여 식용으로도 널리 사용해 왔다. 더덕의 성분으로는 스테롤, N-포르밀하만(N-formylharman), 퍼롤린(perlolyne), 노르하만(norharman), 스쿠알렌(squalene), 더덕향기의 본체라 추정되는 폴리아세틸렌계 물질, 시클로아테놀(cycloartenol), 터페노이드(terpenoid) 성분 및 사포닌(saponin) 등이 밝혀져 있다. Codonopsis lanceolata ) is a perennial herb belonging to the genus Campanulaceae, and has been used for ginseng substitutes since its roots are known as larva (Radix Codonopsis lanceolata). In oriental medicine, it is used for Jinhae, expectorant, detoxification, asthma, etc. In addition to its unique flavors, carbohydrates, and proteins, it is rich in minerals and vitamins such as calcium, phosphorus and iron, and has been widely used for food. Examples of the components of the dodec are sterol, N-formylharman, perlolyne, norharman, squalene, a polyacetylene-based substance presumed to be the main component of the fragrance, cyclobutenol, terpenoid, and saponin have been identified.
국내에서 진행된 더덕에 관한 연구로는 더덕 추출물의 면역작용 증대효과(서정숙, 1996, 한국식품영양학회지, 9(4): 379-384) 및 더덕 에탄올 추출물의 항산화효과(맹연선 등, 1991, 한국식품과학회지 23(3): 311-316) 등이 있고, 최근에는 면역작용을 증강시켜 주는 작용을 시사하는 연구가 보고됨으로서 생체내에서 면역작용을 증강시킬 수 있는 기능식품 소재로 각광받고 있다. Studies on deodeok conducted in Korea include the effects of increasing the immune activity of deodeok extract (Seo Jung-sook, 1996, Korean Journal of Food and Nutrition, 9 (4): 379-384) The Korean Journal of Food Science and Technology 23 (3): 311-316) has recently been reported as a functional food material that can enhance immunity in vivo as a study suggesting an action that enhances immunity.
최근 생약초와 같은 한방제제를 발효하여 유용성분을 증진시키고 약효 및 흡수율을 상승시켜 기능성 식품소재로 활용하는 연구가 진행되고 있다. Recently, researches are being conducted on fermenting herbal preparations such as herbal medicines to enhance useful ingredients and to increase the efficacy and absorption rate as functional food materials.
따라서 본 발명자들은 락토바실러스(Lactobacillus)의 일종인 락토바실러스 브레비스(Lactobacillus brevis)를 이용해 더덕 추출물의 발효물을 아세트아미노펜에 의해 손상된 간세포에 처리하여 간 기능 개선 여부를 조사하였다. 아세트아미노펜은 진통제나 해열제로 널리 알려진 약으로, 만성 알코올 환자에게 사용하였을 경우나 과다복용시 전격성 간염이나 간 부전을 야기하는 약이다(Gyamlani G.G., 2002 Crit. Care). Therefore, the present inventors investigated the improvement of liver function by treating the fermented product of Deodeok extract with hepatocytes damaged by acetaminophen using Lactobacillus brevis , a kind of Lactobacillus. Acetaminophen is a drug widely known as an analgesic or antipyretic. It is a drug that causes chronic hepatitis or liver failure when used in chronic alcohol patients or when overdose (Gyamlani GG, 2002 Crit. Care).
한국공개특허 제2012-0048801호에는 간기능 보호 및 개선용 미나리 발효액 및 그 제조 방법이 개시되어 있으며, 한국등록특허 제0631073호에는 더덕 추출물을 포함하는 알코올성 간질환 및 알코올성 고지혈증의 예방 및 치료용 조성물이 개시되어 있으나, 본 발명에서와 같이 더덕 추출물의 발효물을 유효성분으로 함유하는 간기능 개선용 조성물에 관해서는 밝혀진 바가 없다. Korean Laid-Open Patent Publication No. 2012-0048801 discloses a buttercup fermentation broth for preventing and improving liver function, and a method for preparing the same, and Korean Patent No. 0631073 discloses a composition for preventing and treating alcoholic liver disease and alcoholic hyperlipidemia including Deodeok extract. It is disclosed, but as for the composition for improving liver function containing the fermented product of the deodeok extract as an active ingredient as in the present invention has not been found.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 간기능을 개선시킬 수 있는 기능성 소재의 개발이 요망되고 있으나, 부작용 등 안전성의 문제 때문에 많은 제약을 받고 있는 요즘, 비교적 안전성이 높은 천연물인 더덕 추출물을 젖산균으로 발효시킨 간기능 개선용 조성물을 개발함으로써 본 발명을 완성하였다. The present invention is derived from the above requirements, the present invention, but the development of a functional material that can improve the liver function is desired, but these days, a lot of restrictions due to safety problems such as side effects, relatively high safety natural products The present invention was completed by developing a composition for improving liver function by fermenting an induck extract with lactic acid bacteria.
상기 과제를 해결하기 위해, 본 발명은 더덕 추출물의 발효물을 유효성분으로 함유하는 간기능 개선용 조성물을 제공한다. In order to solve the above problems, the present invention provides a composition for improving liver function containing the fermented product of the deodeok extract as an active ingredient.
또한, 본 발명은 더덕 추출물의 발효물을 함유하는 간기능 개선용 건강식품을 제공한다. In addition, the present invention provides a health food for improving liver function containing a fermented product of Deodeok extract.
본 발명에 따르면, 더덕 추출물을 젖산균으로 발효시킨 조성물은 간기능 개선에 효과적이며, 천연물로부터 얻어진 물질을 이용하기 때문에 부작용을 유발하지 않으며, 안전성을 확보할 수 있어, 간기능 개선을 위한 기능성 식품 산업상 매우 유용한 발명이 될 것이다.According to the present invention, the composition of fermented Deodeok extract with lactic acid bacteria is effective for improving liver function, and because it uses a material obtained from natural products, does not cause side effects, and can ensure safety, and functional food industry for improving liver function. It would be a very useful invention.
도 1은 더덕 추출물의 젖산발효기간에 따른 pH 변화를 나타낸다.
도 2는 더덕 추출물의 젖산발효기간에 따른 산도 변화를 나타낸다.
도 3은 아세트아미노펜(acetaminophen)의 양에 따른 쥐의 간세포 활력을 나타낸다.
도 4는 쥐의 간세포에 아세트아미노펜에 의해 유도된 세포독성에 대해 더덕 추출물 또는 이들 추출물을 젖산균으로 발효한 후 얻은 발효물의 간 보호 작용 효과를 세포생존율(cell viability)로 조사한 결과이다. 쥐의 간세포에 더덕 추출물 또는 이들 추출물을 젖산균으로 발효한 후 얻은 발효물 10ug/mL를 처리하고, 10mM 아세트아미노펜을 24시간 동안 처리하였다. 세포생존율은 MTT 분석을 통해 측정하였다.
도 5는 쥐의 간세포에 아세트아미노펜에 의해 유도된 세포독성에 대해 더덕 추출물 또는 이들 추출물을 젖산균으로 발효한 후 얻은 발효물의 간 보호 작용 효과를 LDH(lactate dehydrogenase) 농도로 조사한 결과이다. 쥐의 간세포에 더덕 추출물 또는 이들 추출물을 젖산균으로 발효한 후 얻은 발효물 10ug/mL를 처리하고, 10mM 아세트아미노펜을 24시간 동안 처리하였다. 간 보호 작용 효과 효과는 LDH 분석으로 측정하였다.
도 6은 쥐의 간세포에 아세트아미노펜에 의해 유도된 세포독성에 대해 더덕 추출물 또는 이들 추출물을 젖산균으로 발효한 후 얻은 발효물의 간 보호 작용 효과를 ALT(Alanine aminotransferase) 농도로 조사한 결과이다. 쥐의 간세포에 더덕 추출물 또는 이들 추출물을 젖산균으로 발효한 후 얻은 발효물 10ug/mL를 처리하고, 10mM 아세트아미노펜을 24시간 동안 처리하였다. 간 보호 작용 효과 효과는 ALT 분석으로 측정하였다.Figure 1 shows the pH change according to the lactic acid fermentation period of the deodeok extract.
Figure 2 shows the change in acidity according to the lactic acid fermentation period of Deodeok extract.
Figure 3 shows the hepatocyte vitality of mice according to the amount of acetaminophen.
Figure 4 is a result of the cell viability of the liver protective effect of the deodeok extract or fermentation obtained after fermenting these extracts with lactic acid bacteria against cytotoxicity induced by acetaminophen in rat liver cells. Rat hepatocytes were treated with deodeok extracts or fermented products obtained after fermenting these extracts with lactic acid bacteria and 10 ug / mL, and 10 mM acetaminophen for 24 hours. Cell viability was measured by MTT assay.
5 is a result of examining the liver protective effect of the fermented product obtained after the fermentation of Deodeok extract or these extracts with lactic acid bacteria against cytotoxicity induced by acetaminophen in rat liver cells by LDH (lactate dehydrogenase) concentration. Rat hepatocytes were treated with deodeok extracts or fermented products obtained after fermenting these extracts with lactic acid bacteria and 10 ug / mL, and 10 mM acetaminophen for 24 hours. Hepatoprotective effect was measured by LDH analysis.
Figure 6 is a result of investigating the hepatoprotective effect of the deodeok extracts or fermentation products obtained after fermenting these extracts with lactic acid bacteria against the cytotoxicity induced by acetaminophen in rat hepatocytes by ALT (Alanine aminotransferase) concentration. Rat hepatocytes were treated with deodeok extracts or fermented products obtained after fermenting these extracts with lactic acid bacteria and 10 ug / mL, and 10 mM acetaminophen for 24 hours. Hepatoprotective effect was measured by ALT analysis.
본 발명의 목적을 달성하기 위해, 본 발명은 더덕 추출물의 발효물을 유효성분으로 함유하는 간기능 개선용 조성물을 제공한다. In order to achieve the object of the present invention, the present invention provides a composition for improving liver function containing the fermented product of the deodeok extract as an active ingredient.
본 발명의 일 구현 예에 따른 조성물에서, 상기 더덕 추출물의 발효물은 더덕 추출물에 젖산균을 첨가 후 발효시켜 제조될 수 있고, 상기 젖산균은 바람직하게는 락토바실러스 속 균주일 수 있으며, 더욱 바람직하게는 락토바실러스 브레비스(Lactobacillus brevis)일 수 있으나, 이에 제한되지 않는다.In the composition according to the embodiment of the present invention, the fermented product of the deodeok extract may be prepared by fermentation after adding lactic acid bacteria to the deodeok extract, the lactic acid bacteria may preferably be a strain of the genus Lactobacillus, more preferably It may be Lactobacillus brevis , but is not limited thereto.
본 발명의 일 구현 예에 따른 조성물에서, 상기 더덕 추출물은 더덕 열수 추출물일 수 있으나, 이에 제한되지 않는다.In the composition according to an embodiment of the present invention, the deodeok extract may be a deodeok hydrothermal extract, but is not limited thereto.
본 발명에서 용어, "추출물(extract)"은 천연물로부터 분리된 활성성분을 의미하며, 물, 유기 용매, 또는 이들의 혼합 용매를 이용하는 추출과정으로 획득할 수 있으며, 추출액, 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 포함한다. 추출한 액은 바로 사용하거나 또는 농축 및/또는 건조하여 사용할 수 있다. 유기 용매를 사용하여 추출하는 경우, 메탄올, 에탄올, 이소프로판올, 부탄올,에틸렌, 아세톤, 헥산, 에테르,클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N,N-디메틸포름아미드(DMF), 디메틸설폭사이드 (DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매인 유기용매를 사용하며 더덕 유효 성분이 파괴되지 않거나 최소화된 조건에서 실온 또는 가온하여 추출할 수 있다. 추출하는 유기용매에 따라 약재의 유효성분의 추출 정도와 손실 정도가 차이날 수 있으므로, 알맞은 유기용매를 선택하여 사용하도록 한다. 추출방법은 특별히 제한되지 않고, 예를 들어 열수 추출, 냉침 추출, 초음파 추출, 및 환류 추출 등이 있다.The term "extract" in the present invention refers to an active ingredient isolated from a natural product. The extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof. Lt; RTI ID = 0.0 > formulated < / RTI > The extracted liquid can be used directly or by concentrating and / or drying. When extracted with an organic solvent, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof is used, and the extract can be extracted at room temperature or warmed under conditions where the active ingredient is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the medicine may be different, so select an appropriate organic solvent. The extraction method is not particularly limited, and examples thereof include hot water extraction, cold needle extraction, ultrasonic extraction, and reflux extraction.
상기 용매 추출물은 부유하는 고체 입자를 제거하기 위하여 추출물을 여과시키는 단계를 추가로 포함할 수 있다. 면, 나일론 등을 이용하여 입자를 걸러내거나 한외여과, 냉동여과법, 원심분리법 등을 사용할 수 있으나, 이에 제한되지 않는다.The solvent extract may further comprise a step of filtering the extract to remove suspended solid particles. Particles may be filtered using cotton, nylon, or the like, or ultrafiltration, freezing, centrifugation, or the like may be used, but is not limited thereto.
추출액을 농축할 경우에는, 감압농축, 역삼투압 농축 등의 방법이 사용될 수 있다. 농축 후 건조 단계는 동결건조, 진공건조, 열풍건조, 분무건조, 감압건조, 포말건조, 고주파건조, 적외선건조 등을 포함하나 이에 제한되지 않는다.When the extract is concentrated, methods such as reduced pressure concentration, reverse osmosis concentration and the like can be used. The post-concentration drying step includes, but is not limited to, freeze drying, vacuum drying, hot air drying, spray drying, vacuum drying, foam drying, high frequency drying, infrared drying and the like.
본 발명의 일 구현 예에 따른 조성물에서, 상기 더덕 추출물의 발효물은 바람직하게는 In the composition according to an embodiment of the present invention, the fermentation of the deodeok extract is preferably
(a) 더덕 열수 추출물에 글루코스 및 탈지분유를 첨가하여 120~122℃에서 13~17분 동안 멸균하는 단계; 및 (b) 상기 (a)단계의 멸균한 첨가물을 식힌 후, 락토바실러스 브레비스(Lactobacillus brevis) 균주를 접종하여 35~39℃에서 12~16일간 발효시켜 제조할 수 있고, (A) sterilizing for 13 to 17 minutes at 120 ~ 122 ℃ by adding glucose and skim milk powder to the deodeok hot water extract; And (b) after cooling the sterilized additive of step (a), Lactobacillus brevis ( Lactobacillus) brevis ) can be prepared by inoculating the strain and fermentation at 35 ~ 39 ℃ 12-16 days,
더욱 바람직하게는 More preferably,
(a) 더덕 열수 추출물에 글루코스 0.8~1.2% 및 탈지분유 0.8~1.2%를 첨가하여 120~122℃에서 13~17분 동안 멸균하는 단계; 및 (b) 상기 (a)단계의 멸균한 첨가물을 식힌 후, 락토바실러스 브레비스(Lactobacillus brevis) 균주를 접종하여 35~39℃에서 12~16일간 발효시켜 제조할 수 있고, (A) sterilizing for 13-17 minutes at 120 ~ 122 ℃ by adding 0.8 ~ 1.2% glucose and 0.8 ~ 1.2% skim milk powder to the deodeok hot water extract; And (b) after cooling the sterilized additive of step (a), inoculated with Lactobacillus brevis strain ( Lactobacillus brevis ) strain can be prepared by fermentation at 35 ~ 39 ℃ 12-16 days,
가장 바람직하게는 Most preferably,
(a) 더덕 열수 추출물에 글루코스 1% 및 탈지분유 1%를 첨가하여 121℃에서 15분 동안 멸균하는 단계; 및 (b) 상기 (a)단계의 멸균한 첨가물을 식힌 후, 락토바실러스 브레비스(Lactobacillus brevis) 균주를 접종하여 37℃에서 14일간 발효시켜 제조할 수 있으나, 이에 제한되지 않는다. (a) adding 1% glucose and 1% skim milk powder to Deodeok hydrothermal extract and sterilizing at 121 ° C. for 15 minutes; And (b) after cooling the sterilized additive of step (a), Lactobacillus brevis ( Lactobacillus) brevis ) can be prepared by inoculating a strain for 14 days at 37 ℃, but is not limited thereto.
또한, 본 발명은 더덕 추출물의 젖산균 발효에 의한 발효물을 함유하는 간 기능 개선용 기능성 식품을 제공한다. In addition, the present invention provides a functional food for improving liver function containing a fermented product by Lactic acid bacteria fermentation of Deodeok extract.
본 발명의 상기 더덕 추출물의 젖산균 발효에 의한 발효물을 식품첨가물로 사용하는 경우, 상기 더덕 추출물의 젖산균 발효에 의한 발효물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 발효물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양의로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다. When the fermented product by lactic acid bacterium fermentation of Deodeok extract of the present invention is used as a food additive, the fermented product by lactic acid bacterium fermentation of Deodeok extract may be added as it is or may be used together with other foods or food ingredients, in a conventional method Can be used accordingly. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, in the preparation of food or beverages, the fermented products of the present invention are added in an amount of up to 15 parts by weight, preferably up to 10 parts by weight relative to the raw materials. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 구체적인 예로, 상기 발효물을 이용하여 농산물, 축산물 또는 수산물의 특성을 살려 변형시키는 동시에 저장성을 좋게 한 가공식품을 제조할 수 있다. 이런 가공식품에는 예를 들어, 과자, 음료, 주류, 발효식품, 통조림, 우유가공식품, 육류가공식품, 국수 등을 포함한다. 과자는 비스킷, 파이, 빵, 캔디, 젤리, 껌, 시리얼(곡물푸레이크 등의 식사대용품류 포함) 등을 포함한다. 음료는 탄산음료, 기능성이온음료, 쥬스(예를 들어, 사과, 배,포도, 알로에, 감귤, 복숭아, 당근, 토마토쥬스 등), 식혜 등을 포함한다. 주류는 청주, 위스키, 소주, 맥주,양주, 과실주 등을 포함한다. 발효식품은 간장, 된장, 고추장 등을 포함한다. 통조림은 수산물 통조림(예를 들어, 참치, 고등어, 공치, 소라 통조림 등), 축산물 통조림(쇠고기, 돼지고기, 닭고기, 칠면조 통조림 등), 농산물 통조림(옥수수, 복숭아, 파인애플 통조림 등)을 포함한다. 우유가공식품은 치즈, 버터, 요구르트 등을 포함한다. 육류가공식품은 돈까스, 비프까스, 치킨까스, 소세지, 탕수육, 너겟류, 너비아니 등을 포함한다. 밀봉포장생면 등의 국수를 포함한다. 이 외에도 상기 조성물은 레토르트식품, 스프류 등에 사용될 수 있다.There is no particular limitation on the kind of the food. As a specific example, the fermented product may be used to produce processed foods that improve the shelf life while simultaneously modifying the characteristics of agricultural products, livestock products or aquatic products. Such processed foods include, for example, confectionery, drinks, liquor, fermented foods, canned foods, milk processed foods, meat processed foods, noodles and the like. The sweets include biscuits, pies, breads, candies, jellies, gums, cereals (including dinner utensils such as cereal flakes). Beverages include carbonated drinks, functional hot drinks, juices (eg, apples, pears, grapes, aloes, citrus fruits, peaches, carrots, tomato juices, etc.), Sikhye, and the like. Alcoholic beverages include sake, whiskey, shochu, beer, liquor and fruit wine. Fermented foods include soy sauce, miso, and kochujang. Canned food includes canned seafood (eg, tuna, mackerel, canned meat, canned seashells, etc.), canned animal products (eg beef, pork, chicken, turkey canned, etc.), canned produce (corn, peaches, canned pineapples, etc.). Milk processed foods include cheese, butter, yogurt and the like. Meat processed foods include pork cutlet, beef cutlet, chicken cutlet, sausage, sweet and sour pork, nuggets, nubucki, and the like. And noodles such as sealed packaging raw noodles. In addition, the composition may be used in retort food, soup and the like.
또한, 상기 발효물을 이용하여 기능성식품, 건강식품 또는 건강보조식품을 제조할 수 있다. 기능성식품, 건강식품 또는 건강보조식품은 영양 기능 외에도 생리활성 성분을 포함하여 생체조절 기능을 제공하는 식품을 의미하고, 본 발명의 발효물은 간 기능 회복 및 보호 효과를 가지는 상기 여러 가지의 특정 천연 추출물을 유효 성분으로 포함하므로 기능성식품, 건강식품 또는 건강보조식품 등의 제조에 이용될 수 있다.
In addition, the fermented product may be used to produce a functional food, health food or health supplement food. Functional food, health food or dietary supplement means a food that provides a bioregulatory function, including a physiologically active ingredient in addition to the nutritional function, the fermented product of the present invention has a variety of specific natural Since the extract is included as an active ingredient, it can be used in the manufacture of functional foods, health foods or health supplements.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
재료 및 방법Materials and methods
1) 원료1) Raw materials
더덕은 동부생약조합법인에서 구입하여 사용하였다.Deodeok was purchased from Dongbu Herbal Cooperative Corporation.
2) 젖산균2) Lactic Acid Bacteria
젖산균 발효에는 락토바실러스 브레비스(Lactobacillus brevis)를 사용하였다. Lactobacillus brevis was used for lactic acid bacteria fermentation.
3) 시료제조 방법3) Sample preparation method
더덕 추출물과 젖산균 발효물에 대한 제조 방법은 다음과 같다. 즉, 더덕 1kg에 정제수 4L를 넣고 100℃에서 3시간 동안 추출하였고, 농도는 7.5 브릭스(brix)였다. 각 추출물의 농도가 각각 1%, 3%, 5%가 포함되도록 최종 부피 1L가 되도록 증류수로 조정한 후 글루코스(glucose) 1%, 탈지분유 1%를 첨가하여 121℃에서 15분 동안 멸균시켰다. 상온에서 식힌 상기 멸균된 추출물에 젖산균 배양액 10㎖를 접종 후 37℃에서 14일간 발효시킨 것을 사용하였다. 대조구는 젖산균 발효 처리를 수행하지 않은 멸균된 각 추출물을 그대로 사용하였다.The manufacturing method for the deodeok extract and lactic acid bacteria fermentation is as follows. That is, 4L of purified water was added to 1 kg of Deodeok and extracted at 100 ° C. for 3 hours, and the concentration was 7.5 brix. Each extract was adjusted to distilled water to a final volume of 1 L to include 1%, 3%, and 5%, respectively, and then sterilized at 121 ° C. for 15 minutes by adding 1% glucose and 1% skim milk powder. 10 ml of lactic acid bacterium culture solution was inoculated into the sterilized extract cooled at room temperature and then fermented at 37 ° C. for 14 days. As a control, sterilized extracts which were not subjected to lactic acid bacteria fermentation were used as they were.
4) 일반성분 분석4) General ingredient analysis
일반성분은 AOAC(Association of Official Analytical Chemists) 방법에 따라 분석하였다. 즉 수분은 시료 5g을 각각 칭량병에 담고 105℃ 드라이 오븐에서 항량이 될 때까지 건조시켜 무게를 측정하여 함량을 구하고, 조회분은 시료 약 2g을 250℃에서 예비 회화한 후 600℃에서 회화하여 직접 회화법으로, 조단백질의 함량은 캘달(Kjeldahl)법으로 측정된 질소량에 질소계수 6.25를 곱하여 산출하였으며 조지방의 함량은 시료를 건조시킨 후 속슬레(Soxhlet) 추출법으로 측정하였다. 또한, 조섬유는 헨너베르크스토만(Henneberg Stohmann) 개량한 AOAC법으로 분석하고, 가용성 무질소물의 함량은 총량에서 수분, 조회분, 조단백질, 조지방, 조섬유의 함량을 뺀 값으로 산출하였다.
General ingredients were analyzed according to the Association of Official Analytical Chemists (AOAC) method. In other words, 5g of each sample is placed in a weighing bottle and dried in a 105 ℃ dry oven until it is weighed. The weight is measured and the content is calculated. Inquiry content is pre-incubated at 250 ° C after about 2g of sample. In the direct ingestion method, the crude protein content was calculated by multiplying the nitrogen content measured by the Kjeldahl method by the nitrogen coefficient of 6.25, and the crude fat content was measured by Soxhlet extraction method after drying the sample. In addition, crude fiber was analyzed by the Hennerberg Stohmann improved AOAC method, and the content of soluble nitrogen was calculated by subtracting moisture, crude ash, crude protein, crude fat, crude fiber content from the total amount.
5) 유리당 분석5) Free Sugar Analysis
유리당 성분은 윌슨(Wilson) 등의 방법에 따라 분석하였다. 즉, 시료 20g에 증류수를 가해 균질기로 마쇄하고 교반 후 침출시켜 100 mL로 정용한 다음 원심분리(3,000 분당회전수, 30분)하여 상등액을 취해 여과(Whatman No.2)하였다. 여과한 여액은 Sep-pak C18으로 정제시킨 다음 0.45㎛ 막 필터(Millipore Co., 미국)로 여과하여 HPLC용 분석 시료로 사용하였으며, 함량은 외부표준법으로 계산하고 HPLC 조건은 표 1과 같다.
The free sugar component was analyzed according to the method of Wilson et al. That is, distilled water was added to 20 g of the sample, ground with a homogenizer, stirred, leached to a constant volume of 100 mL, centrifuged (3,000 rpm, 30 minutes), and the supernatant was collected and filtered (Whatman No. 2). The filtered filtrate was purified by Sep-pak C 18 and then filtered through a 0.45㎛ membrane filter (Millipore Co., USA) was used as an analytical sample for HPLC, the content is calculated by the external standard method and HPLC conditions are shown in Table 1.
6) 유기산 분석6) Organic Acid Analysis
유기산 분석은 유리당 분석의 전처리 과정과 동일하게 처리하여 추출된 여액을 HPLC를 이용하여 표 2의 조건으로 분석하였다.Organic acid analysis was performed in the same manner as the pretreatment of free sugar analysis, and the filtrate extracted was analyzed under the conditions of Table 2 using HPLC.
7) 아미노산 분석7) Amino Acid Analysis
가) 구성 아미노산 분석A) Amino Acid Analysis
시료 1g을 시험관에 넣고 6N-HCl 용액 10mL를 가한 후 110℃에서 24시간 가수분해 시켜서 얻은 여액을 원심분리하고, 상등액을 50℃에서 농축하여 염산과 물을 완전히 증발시킨 후, 20mM HCl(pH 2.2)을 사용하여 5mL로 정용한 다음 0.45㎛ 막 필터로 여과한 다음 여액을 취하여 AccQ-Tag 시약을 사용하여 유도체화 시킨 후 고성능액체크로마토그래피용 분석 시료로 사용하였다. 분석조건은 표 3과 같고, 아미노산 함량은 적분기(integrator)에 의한 외부표준법으로 계산하였다. 1 g of sample was added to a test tube, 10 mL of 6N-HCl solution was added, and the filtrate obtained by hydrolysis at 110 ° C. for 24 hours was centrifuged. The supernatant was concentrated at 50 ° C. to completely evaporate hydrochloric acid and water, followed by 20 mM HCl (pH 2.2). ) Was filtered to 0.4 mL membrane filter, and the filtrate was derivatized with AccQ-Tag reagent and used as analytical sample for high performance liquid chromatography. Analysis conditions are shown in Table 3, and the amino acid content was calculated by an external standard method by an integrator.
나) 유리 아미노산 분석 B) free amino acid analysis
시료의 유리 아미노산 분석은 유리당 정량과 같은 방법으로 전처리하여 얻은 여액을 Ohara와 Ariyosh의 방법에 준해 분석하였다. 여액 10ml에 설포살리실산(sulfosalicylic acid) 25 mg을 첨가하여 4℃에서 4시간 동안 방치시킨 후 원심분리(50000 분당회전수, 30분)하여 단백질 등을 제거하고, 상등액을 0.45㎛ 막 필터로 여과하여 얻은 여액을 AccQ-Tag 시약으로 유도체화시킨 후 HPLC로 분석하였으며 분석조건은 표 3과 같다.Free amino acid analysis of the sample was analyzed by Ohara and Ariyosh's method for filtrate obtained by pretreatment in the same way as free sugar quantification. 25 mg of sulfosalicylic acid was added to 10 ml of the filtrate, which was allowed to stand at 4 ° C. for 4 hours, followed by centrifugation (50000 rpm, 30 minutes) to remove proteins, and the supernatant was filtered through a 0.45 μm membrane filter. The obtained filtrate was derivatized with AccQ-Tag reagent and analyzed by HPLC. The analysis conditions are shown in Table 3.
8) pH 측정 8) pH measurement
시료의 발효기간 중 pH의 변화는 시료 20 mL를 취하여 pH 미터(Orion 940. 미국)를 사용하여 측정하였다.
The pH change during the fermentation period of the sample was measured using a pH meter (Orion 940. USA) taking 20 mL of the sample.
9) 산도 측정9) pH measurement
시료의 발효기간 중 총산 함량은 시료를 원심분리하여 상징액 10mL를 취해 1% 페놀프탈레인(phenolphthalein)을 지시약으로 하고, 01 N NaOH 용액으로 적정한 후 젖산계수 0.009를 곱하여 젖산(lactic acid)으로 환산한다.
The total acid content during the fermentation period of the sample was centrifuged to take 10 mL of the supernatant, and 1% phenolphthalein was used as an indicator. After titration with 01 N NaOH solution, the total acid content was multiplied by lactic acid coefficient 0.009 to convert lactic acid.
10) 간 보호 및 간기능개선 실험10) Liver protection and liver function improvement experiment
가) 콜라게나제 관류(Collagenase perfusion)Collagenase perfusion
스프레이그-다우레이(Sprague-Dawley; SD) 쥐(rat)의 간세포는 Berry와 Friend의 방법을 수정한 2단계 콜라게나제 관류 방법으로 분리하였다. 간세포를 얻기 위해 SD 쥐는 에테르(ether)로 흡입 마취시키고 70% 에탄올로 복부를 소독한 후, 개복하여 우심방을 절개하여 혈액이 제거될 수 있도록 하고 좌심실에 21 게이지 주사기로 한의평형염액(hank's balanced salt solution; HBSS) 150 ml을 혈관 내로 주입하였다. 혈액을 제거한 후, 콜라게나제(100 U/ml)가 포함된 한의평형염액을 100 ml 재순환시켜 간세포가 유리되게 하였다. 간조직을 떼어내어 100 mm 배양접시에서 한의평형염액 60 ml를 첨가하고 No. 11 블레이드(blade)로 잘라 하나의 세포들을 얻을 수 있었다. 이 세포 현탁액에 콜라게나제를 제거하기 위해 3회 웨이머스(Waymouth)의 MB 752/1 배지(5% 소태아혈청(fetal bovine serum), 2.0 mg/ml 소혈청 알부민(bovine serum albumin), 10-6 M 덱사메사손(dexamethasone), 10-7 M 인슐린, 5.32 x 10-2 M L-세린, 4.09 x 10-2 M L-알라닌, 2.67 x 10-2 M NaHCO3, 100 IU/ml 페니실린, 100 IU/ml 스트레토마이신(streptomycin), 50 /ml 젠타마이신설페이트(gentamicin sulfate))으로 헹궈주었다. 이렇게 얻은 간세포는 5 x 105 cell/ml로 희석하여 콜라겐(collagen)으로 코팅되어 있는 96웰 플레이트(96- well plate) 에 4시간 동안 부착시킨 후, 각 시료를 처리하였다.Sprague-Dawley (SD) rat hepatocytes were isolated by Berry and Friend's modified two-stage collagenase perfusion method. To obtain hepatocytes, SD rats were anesthetized with ether, sterilized the abdomen with 70% ethanol, and then opened to open the right atrium to remove the blood and to remove the Hank's balanced salt with a 21 gauge syringe in the left ventricle. solution; HBSS) 150 ml was injected into the blood vessel. After removing the blood, 100 ml of Korean herbal equilibrium saline containing collagenase (100 U / ml) was recycled to release the hepatocytes. Remove liver tissue and add 60 ml of oriental equilibrium saline solution in 100 mm culture dish. One blade was obtained by cutting with 11 blades. To remove collagenase in this cell suspension, three times Weymouth MB 752/1 medium (5% fetal bovine serum, 2.0 mg / ml bovine serum albumin, 10) -6 M dexamethasone, 10 -7 M insulin, 5.32 x 10 -2 M L-serine, 4.09 x 10 -2 M L-alanine, 2.67 x 10 -2 M NaHCO 3 , 100 IU / ml penicillin Rinse with 100 IU / ml streptomycin, 50 / ml gentamicin sulfate. Thus obtained hepatocytes were diluted to 5 x 10 5 cell / ml and attached to a 96-well plate (96-well plate) coated with collagen (collagen) for 4 hours, and then treated with each sample.
나) 세포독성분석B) Cytotoxicity analysis
쥐의 일차(primary) 간 세포는 96웰 플레이트에 5 x 105 cell/ml의 농도로 배양하여 시료를 처리하였다. 24시간 처리 후, 0.5 μg/ml tetrazolium-based colorimetric(MTT)를 첨가하여 4시간 동안 포르마잔(formazan)을 형성시켰다. 반응이 끝나면 배지를 제거하고 디메틸 설폭시드(dimethyl sulfoxide; DMSO)로 포르마잔을 용해시켜 마이크로플레이트 리더기로 540 nm에서 흡광도를 측정하였다. 각 시료의 세포 생존률은 무처리군이 컨트롤을 100%로 하여 계산하였다.The primary liver cells of the rats were treated with samples by incubating in 96 well plates at a concentration of 5 x 10 5 cells / ml. After 24 hours of treatment, formazan was formed for 4 hours by adding 0.5 μg / ml tetrazolium-based colorimetric (MTT). After the reaction, the medium was removed, and formazan was dissolved in dimethyl sulfoxide (DMSO), and the absorbance was measured at 540 nm using a microplate reader. Cell viability of each sample was calculated by the untreated group with 100% control.
다) 간기능 검사C) liver function test
간기능 검사를 하기 위해 BlueGene Co.(상하이, 중국)에서 구매한 쥐 알라닌 트랜스아미나아제(alanine transaminase; ALT), 쥐 젖산탈수소효소(lactate dehydrogenase; LDH) ELISA 키트를 사용하여 효소를 정량적으로 측정하였다.
Enzymes were quantitatively measured using a rat alanine transaminase (ALT) and rat lactate dehydrogenase (LDH) ELISA kit purchased from BlueGene Co. (Shanghai, China) for liver function tests. .
실시예Example 1. 더덕의 일반성분, 유리당, 유기산 및 아미노산 함량 분석 1. Analysis of general ingredients, free sugars, organic acids and amino acids in Deodeok
1) 일반성분 함량1) General ingredient content
본 발명에 사용된 더덕의 일반성분 함량은 표 4와 같다. 수분 함량은 11.45% 로 나타났으며, 회분 함량은 3.04%, 조단백질 함량은 13.32% 로 나타났다. 조지방 함량은 2.67%, 조섬유 함량은 10.49%로 나타났다.Of deodeok used in the present invention General ingredient contents are shown in Table 4. The moisture content was 11.45%, the ash content was 3.04%, and the crude protein content was 13.32%. Crude fat content was 2.67% and crude fiber content was 10.49%.
2) 유리당 함량2) free sugar content
본 발명에 사용된 더덕 및 추출물의 유리당 함량은 표 5와 같다. 주요 당으로는 포도당과 과당으로 나타났다. 맥아당은 건조 시료구에서 1.41%로 나타났으나, 추출물을 이용한 시료구에서는 검출되지 않았다. Of deodeok and extract used in the present invention Free sugar content is shown in Table 5. The main sugars were glucose and fructose. Maltose was found to be 1.41% in the dry sample, but was not detected in the sample using the extract.
자당은 더덕과 더덕추출물에서 각각 5.14%, 0.17% 검출되었다. 더덕 추출물 함량을 달리하여 제조한 젖산발효액의 유리당 함량은 젖산균 발효전에 비하여 총 유리당 함량을 비롯하여 모든 유리당의 함량이 낮아졌다. Sucrose was detected in Deodeok and Deodeok extracts by 5.14% and 0.17%, respectively. The free sugar content of the lactic acid fermentation solution prepared by varying the deodeok extract content was lower than all the free sugars, including the total free sugar content, before the lactic acid bacteria fermentation.
3) 유기산 함량3) organic acid content
본 발명에 사용된 더덕의 유기산 함량은 표 6과 같다. 검출된 주요 유기산은 사과산, 젖산, 초산이었다. 추출물 함량에 따른 총유기산 함량변화는 젖산균을 접종하지 않은 시험구들에서 추출물들의 첨가량에 비례하여 총 유기산 함량이 높아졌다. 최종산물인 젖산균 발효물들은 더덕추출물 첨가량이 증가할수록 총 유기산 함량이 감소함을 확인하였다.
Organic acid content of the deodeok used in the present invention is shown in Table 6. The main organic acids detected were malic acid, lactic acid and acetic acid. The total organic acid content according to the extract content was increased in proportion to the amount of extracts added in the test groups not inoculated with lactic acid bacteria. Lactic acid bacteria fermentation, the final product, was confirmed that the total organic acid content decreases as the amount of extract added.
4) 아미노산 함량4) amino acid content
가) 구성 아미노산 함량A) Amino Acid Content
본 발명에 사용된 시료의 구성 아미노산 분석 결과는 표 7과 같다. 시료의 구성 아미노산은 총 16종의 아미노산이 검출되었으며, 총 함량은 더덕 9,955.83 mg%, 더덕추출물 2,259.91 mg% 로 나타났다. 더덕과 더덕추출물의 주요 구성 아미노산으로는 아르기닌, 트레오닌(threonine), 글루탐산 등으로 나타났다.Amino acid analysis results of the samples used in the present invention are shown in Table 7. A total of 16 amino acids were detected in the sample, and the total content was 9,955.83 mg% of Deodeok and 2,259.91 mg% of Deodeok extract. The major constituent amino acids of deodeok and deodeok extracts were arginine, threonine and glutamic acid.
나) 유리 아미노산 함량B) free amino acid content
본 발명에 사용된 시료의 유리 아미노산 분석 결과는 표 8과 같다. 시료의 유리 아미노산도 구성 아미노산과 같이 총 16종의 아미노산이 검출되었으며, 총 유리 아미노산 함량은 더덕 1,075.41mg%, 더덕 추출물 244.88 mg%로 나타났다. 더덕과 더덕추출물의 주요 유리아미노산은 아르기닌, 프롤린 등으로 나타났으며, 트레오닌과 글리신(glycine)은 추출물들에서 검출되지 않았다.Free amino acid analysis results of the samples used in the present invention are shown in Table 8. Like the constituent amino acids, a total of 16 amino acids were detected in the sample, and total free amino acid contents were 1,075.41 mg% and Deodeok extract 244.88 mg%. The major free amino acids of Deodeok and Deodeok extracts were arginine and proline, and threonine and glycine were not detected in the extracts.
실시예Example 2. 더덕 추출물의 젖산균 발효에 따른 2. Lactic Acid Bacteria Fermentation of Deodeok Extract pHpH 변화 및 젖산균 Changes and lactic acid bacteria 발효물의Fermented 산도 변화 PH change
1) 젖산 발효에 따른 pH 변화1) pH change by lactic acid fermentation
더덕 추출물을 첨가한 시료들의 발효 기간에 따른 pH 변화는 도 1과 같다. 더덕 추출물에서 pH는 1일과 3일 사이에 가장 크게 낮아졌으며, 그 후로는 큰 변화 없이 일정 pH를 유지하였다. 최총 pH는 1% 첨가 발효물이 가장 낮게 나타났으며, 그 다음으로 3% 첨가 발효물과 5% 첨가 발효물 순으로 낮게 나타났다. PH change according to the fermentation period of the samples to which the deodeok extract is added is as shown in FIG. The pH of the deodeok extract was the lowest between 1 and 3 days, after which the constant pH was maintained without significant change. The total pH was lowest with 1% added fermentation, followed by 3% added fermentation and 5% added fermentation.
2) 젖산 발효물의 산도 변화2) Change in Acidity of Lactic Acid Fermentation
더덕 추출물에서의 산도 변화는 도 2와 같다. 더덕 추출물 1% 첨가 발효물이 가장 높은 산도를 나타냈으며 발효기간 5일에서 11일 사이에 크게 증가하다가 점차 감소하는 모습을 보였다. 더덕추출물 3%첨가 발효물과 5%첨가 발효물에서는 발효기간 7일 까지는 산도가 증가하였으며, 그 후로는 큰 차이가 나타나지 않았다.
Acidity change in the deodeok extract is shown in FIG. The fermented product added 1% of Deodeok extract showed the highest acidity, and greatly increased from 5 to 11 days of fermentation period and then gradually decreased. Acidity increased up to 7 days of fermentation in 3% fermented and 5% fermented extracts of Deodeok extract, and there was no significant difference thereafter.
실시예Example 3. 더덕 추출물의 젖산균 3. Lactic Acid Bacteria of Deodeok Extract 발효물의Fermented 간 보호 및 간기능개선 효과 Liver protection and liver function improvement effect
가) 아세트아미노펜(Acetaminophen)의 세포독성에 대한 더덕 추출물의 젖산균 발효물의 효과A) Effect of Lactic Acid Bacteria Fermentation of Deodeok Extract on Cytotoxicity of Acetaminophen
쥐 일차 간세포에 아세트아미노펜을 0, 0.5, 2.5, 10, 50 mM의 농도로 처리한 후 24시간 동안 배양하였다. 반응이 끝난 각 웰(well)에 MTT 실험한 결과, 농도에 의존적으로 세포 생존율이 감소하였다. 간독성을 유발하기 위해 10 mM 아세트아미노펜을 처리하였을 때, 간세포 독성이 일어나 10 mM 아세트아미노펜으로 간독성을 유발하여 간세포 보호효과 및 간기능 개선효과 실험을 실시하였다(도 3).Rat primary hepatocytes were treated with acetaminophen at concentrations of 0, 0.5, 2.5, 10, 50 mM and then incubated for 24 hours. As a result of MTT experiment in each well after the reaction, cell viability decreased depending on the concentration. When 10 mM acetaminophen was treated to induce hepatotoxicity, hepatocyte cytotoxicity was induced, and hepatotoxicity was induced with 10 mM acetaminophen, and hepatocellular protective effect and liver function improvement effect experiment were performed (FIG. 3).
더덕 추출물 및 젖산균으로 발효한 더덕 추출물의 간세포 보호효과를 확인하기 위해 10 mM 아세트아미노펜과 각 시료 10 ㎍/mL을 처리하여 간 독성으로 인한 간세포 보호효과를 확인하였다(도 4). 그 결과 더덕 추출물의 세포생존도가 125.2%로 측정되었으며 젖산균으로 발효한 더덕 추출물은 132.4%로 측정되었다. 이는, 추출물들이 간세포 보호를 하였지만, 젖산균으로 발효한 더덕 추출물들은 7.2% 정도 간세포 보호효과가 높아졌음을 확인할 수 있었다. 이러한 결과로 볼 때 추출물보다 젖산균으로 발효를 하였을 경우 간세포 보호효과를 강화하였다고 판단된다.
In order to confirm the hepatocellular protective effect of the deodeok extract fermented with deodeok extract and lactic acid bacteria, 10 mM acetaminophen and 10 ㎍ / mL of each sample was confirmed to confirm the hepatocyte protective effect due to liver toxicity (Fig. 4). As a result, the cell viability of Deodeok extract was measured to be 125.2%, and the Deodeok extract fermented with lactic acid bacteria was measured to be 132.4%. It was confirmed that the extracts were hepatocellular protection, but the deodeok extracts fermented with lactic acid bacteria increased the hepatocellular protection by 7.2%. These results suggest that the fermentation with lactic acid bacteria rather than extracts strengthened the hepatocellular protective effect.
나) 추출물의 간기능 개선효과 검사(LDH)B) Liver function improvement effect test (LDH)
10 mM 아세트아미노펜으로 간세포에 독성을 일으켰을 때, 분비되는 젖산탈수소효소(LDH)를 측정한 결과, 대조구보다 증가되는 것을 확인할 수 있었다(도 5). 더덕 추출물은 49.7 ng/mL로 측정되었지만 젖산균으로 발효한 더덕 추출물은 10.0 ng/mL로 측정되어 젖산균으로 발효하였을 때 간기능 개선효과가 39.7 ng/mL 만큼 젖산탈수소효소의 분비량이 낮아져 추출물보다 젖산균으로 발효한 추출물이 간기능 개선효과가 좋아졌음을 확인할 수 있었다.
When 10 mM acetaminophen was toxic to hepatocytes, the secretion of lactate dehydrogenase (LDH) secreted was confirmed to be increased compared to the control (FIG. 5). Deodeok extract was measured as 49.7 ng / mL, but deodeok extract fermented with lactic acid bacteria was measured as 10.0 ng / mL, and when fermented with lactic acid bacteria, the secretion of lactate dehydrogenase was lowered by 39.7 ng / mL. The fermented extract was confirmed to improve the liver function.
다) 추출물의 간기능 개선효과 검사(ALT) C) Liver function improvement effect test (ALT)
10 mM의 아세트아미노펜에 의해 간 독성을 유발시킨 일차 쥐 간세포의 ALT가 증가하였다(도 6). 더덕 추출물들은 젖산균으로 발효시킬 경우 4.5 ng/mL 만큼 ALT의 분비량이 줄어들었음을 확인하였으며, 이러한 결과는 추출물보다 젖산균으로 발효한 추출물이 간기능 개선에 보다 탁월함을 확인하였다.ALT of primary rat hepatocytes induced by hepatic toxicity with 10 mM acetaminophen increased (FIG. 6). Deodeok extracts were confirmed to decrease the secretion of ALT by 4.5 ng / mL when fermented with lactic acid bacteria, these results confirmed that the extract fermented with lactic acid bacteria than the extract was superior to liver function.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120058460A KR101344055B1 (en) | 2012-05-31 | 2012-05-31 | Composition for improving liver function containing fermented liquor of Codonopsis lanceolata extract as effective component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120058460A KR101344055B1 (en) | 2012-05-31 | 2012-05-31 | Composition for improving liver function containing fermented liquor of Codonopsis lanceolata extract as effective component |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130134733A KR20130134733A (en) | 2013-12-10 |
KR101344055B1 true KR101344055B1 (en) | 2013-12-24 |
Family
ID=49982312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120058460A KR101344055B1 (en) | 2012-05-31 | 2012-05-31 | Composition for improving liver function containing fermented liquor of Codonopsis lanceolata extract as effective component |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101344055B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160046206A (en) * | 2014-10-20 | 2016-04-28 | 주식회사 어람 | The fermenting method of Codonopsis lanceolata for enhancing recognition ability improvement activity of Codonopsis lanceolata |
KR20180059588A (en) | 2016-11-25 | 2018-06-05 | 뉴트라팜주식회사 | Food composition comprising pine tree bark extract for improving liver function and relieving hangover |
KR20220155507A (en) | 2021-05-14 | 2022-11-23 | 동의초석잠영농조합법인 | Composition for removing hangover and maintaining the health of liver comprising extracts of stachys sieboldi miq and cirsium japonicum |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100631073B1 (en) | 2006-04-03 | 2006-10-04 | 연세대학교 산학협력단 | Composition for preventing and treating alcoholic liver disease and alcoholic hyperlipidemia comprising the extract of codonopsis lanceolata |
-
2012
- 2012-05-31 KR KR1020120058460A patent/KR101344055B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100631073B1 (en) | 2006-04-03 | 2006-10-04 | 연세대학교 산학협력단 | Composition for preventing and treating alcoholic liver disease and alcoholic hyperlipidemia comprising the extract of codonopsis lanceolata |
Non-Patent Citations (2)
Title |
---|
DAUM 블로그(2011.12.15) |
논문1: KOREAN J.MEDICAL CROP SCI (2009) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160046206A (en) * | 2014-10-20 | 2016-04-28 | 주식회사 어람 | The fermenting method of Codonopsis lanceolata for enhancing recognition ability improvement activity of Codonopsis lanceolata |
KR101696835B1 (en) | 2014-10-20 | 2017-01-17 | 주식회사 어람 | The fermenting method of Codonopsis lanceolata for enhancing recognition ability improvement activity of Codonopsis lanceolata |
KR20180059588A (en) | 2016-11-25 | 2018-06-05 | 뉴트라팜주식회사 | Food composition comprising pine tree bark extract for improving liver function and relieving hangover |
KR20220155507A (en) | 2021-05-14 | 2022-11-23 | 동의초석잠영농조합법인 | Composition for removing hangover and maintaining the health of liver comprising extracts of stachys sieboldi miq and cirsium japonicum |
Also Published As
Publication number | Publication date |
---|---|
KR20130134733A (en) | 2013-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101705548B1 (en) | Composition for enhancing immune response comprising extract of Apios americana Medikus or fermented extract of the same | |
KR20160130651A (en) | Composition for Anti-Diabetes and Eyesight Recovery Using Aronia Fruits and Mulberry | |
KR101320738B1 (en) | The method of extracting carotinoid pigments of micro algae and composition comprising the extracted fucoxanthin for preventing or treating obesity or diabetes | |
JP2003135028A (en) | Functional food for health | |
KR101344055B1 (en) | Composition for improving liver function containing fermented liquor of Codonopsis lanceolata extract as effective component | |
KR101344054B1 (en) | Composition for improving liver function containing fermented liquor of Hovenia dulcis Thunb extract as effective component | |
CN101810324A (en) | Cordyceps drink and processing method thereof | |
TW201034584A (en) | Process for producing γ-aminobutyric acid-rich material | |
KR100699782B1 (en) | Food composition for improving liver function comprising a Lonicera caerulea L. var. edulis extract | |
CN110693025B (en) | Composition with synergistic effect of multifunctional components for reducing blood sugar and application thereof | |
KR101446528B1 (en) | Vinegar Composition Fermented with Black Garlic and Preparation Method Thereof | |
KR101704123B1 (en) | Method for seperating bee venom containing active amines and food composition thereof | |
KR101408101B1 (en) | Food for improving liver function comprising black rice culture of Lentinus edodes mycelia adding Hovenia dulcis extract as effective component | |
CN103349079B (en) | A kind of production method of functional milk beverage with cepe | |
KR20160079269A (en) | Anti-inflammatory pharmaceutical composition and health functional food containing artemisia fermentation extract | |
US20080044498A1 (en) | Therapeutic or prophylactic agent, and method of treating or preventing a disease | |
KR20080100942A (en) | Compositions for improving liver function | |
KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
KR20120019311A (en) | Composition for immunostimulation which comprises polysaccharide from fermented ginseng with phellinus linteus to enhance the immune function | |
KR101307051B1 (en) | Nature seasoning using micro algae protein hydrolysate and the manufacturing method thereof | |
KR20210155901A (en) | Composition for enhancing immunity comprising NueDongChungHaCho(Paecilomyces tenuipes) water extract | |
JP2020019756A (en) | Nitric oxide production promoter | |
KR101696342B1 (en) | Composition for Anti-Diabetes | |
KR20140080756A (en) | Method for producing fermented Gastrodiae rhizoma with increased functionality using mixed fermentation strain and fermented Gastrodiae rhizoma produced by the method | |
KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170920 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20181008 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190930 Year of fee payment: 7 |